Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer

NanoString Technologies (NASDAQ: NSTG ) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in Clinical Cancer Research showed that the PAM50 assay, on which the company's Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based, accurately assessed